Hydromorphone is in a group of drugs called narcotic pain relievers. Hydromorphone (HCl) is a phenantherne derivative with agonist activity on opiate receptors. Hydromorphone (HCl) is a, semisynthetic analog of morphine, but more potent than morphine. Due to its potency, Hydromorphone (HCl) is often used to relieve severe pain in cancer patients, although its short duration of action can limit its utility. Although all opiates can potentially suppress the cough reflex, hydromorphone is rarely used for this purpose. The drug is available for oral use as well as for parenteral administration. Hydromorphone is a schedule C-II controlled substance and was approved by the FDA in 1984.